Matching articles for "afamitresgene autoleucel"

In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)

   
The Medical Letter on Drugs and Therapeutics • October 14, 2024;  (Issue 1713)
Afamitresgene autoleucel (Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA...
Afamitresgene autoleucel (Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen. It is the first gene therapy to be approved in the US for treatment of synovial sarcoma. Accelerated approval of the immunotherapy was based on the overall response rate and duration of response.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e169-70 | Show Full IntroductionHide Full Introduction